QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.081901v1 313/3/1370    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kandimalla, K. K. Articles by Poduslo, J. F. Search for Related Content PubMed PubMed Citation Articles by Kandimalla, K. K. Articles by Poduslo, J. F.

NEUROPHARMACOLOGY

Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of ¹²⁵I-Amyloid Protein 40 in Wild-Type and Alzheimer's Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation

Molecular Neurobiology Laboratory, Departments of Neurology, Neuroscience, and Biochemistry/Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota

Amyloid plaques are formed in the extracellular space of Alzheimer's disease (AD) brain due to the accumulation of amyloid (A) proteins such as A40. The relationship between A40 pharmacokinetics and its accumulation within and clearance from the brain in both wild-type (WT) and AD transgenic mice (APP,PS1) was studied to understand the mechanism of amyloid plaque formation and the potential use of A40 as a probe to target and detect amyloid plaques. In both WT and APP,PS1 mice, the ¹²⁵I-A40 tracer exhibited biexponential disposition in plasma with very short first and second phase half-lives. The ¹²⁵I-A40 was significantly metabolized in the liver kidney > spleen. Coadministration of exogenous A40 inhibited the plasma clearance and the uptake of ¹²⁵I-A40 at the blood-brain barrier (BBB) in WT animals but did not affect its elimination from the brain. The ¹²⁵I-A40 was shown to be metabolized within and effluxed from the brain parenchyma. The rate of efflux from APP,PS1 brain slices was substantially lower compared with WT brain slices. Since the A40 receptor at the BBB can be easily saturated, the blood-to-brain transport of A40 is less likely to be a primary contributor to the amyloid plaque formation in APP,PS1 mice. The decreased elimination of A40 from the brain is most likely responsible for the amyloid plaque formation in the brain of APP,PS1 mice. Furthermore, inadequate targeting of A40 to amyloid plaques, despite its high BBB permeability, is due to the saturability of A40 transporter at the BBB and its metabolism and efflux from the brain.

Address correspondence to: Dr. Joseph F. Poduslo, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905. E-mail: poduslo.joseph{at}mayo.edu

This article has been cited by other articles:

				N.-W. Hu, I. M. Smith, D. M. Walsh, and M. J. Rowan Soluble amyloid-{beta} peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo Brain, September 1, 2008; 131(9): 2414 - 2424. [Abstract] [Full Text] [PDF]

				C. Tamaki, S. Ohtsuki, and T. Terasaki Insulin Facilitates the Hepatic Clearance of Plasma Amyloid beta-Peptide (1 40) by Intracellular Translocation of Low-Density Lipoprotein Receptor-Related Protein 1 (LRP-1) to the Plasma Membrane in Hepatocytes Mol. Pharmacol., October 1, 2007; 72(4): 850 - 855. [Abstract] [Full Text] [PDF]

				K. K. Kandimalla, T. M. Wengenack, G. L. Curran, E. J. Gilles, and J. F. Poduslo Pharmacokinetics and Amyloid Plaque Targeting Ability of a Novel Peptide-Based Magnetic Resonance Contrast Agent in Wild-Type and Alzheimer's Disease Transgenic Mice J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 541 - 549. [Abstract] [Full Text] [PDF]

				K. K. Kandimalla, G. L. Curran, S. S. Holasek, E. J. Gilles, T. M. Wengenack, M. Ramirez-Alvarado, and J. F. Poduslo Physiological and Biophysical Factors That Influence Alzheimer's Disease Amyloid Plaque Targeting of Native and Putrescine Modified Human Amyloid beta40 J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 17 - 25. [Abstract] [Full Text] [PDF]